TRIM25: A Global Player of Cell Death Pathways and Promising Target of Tumor-Sensitizing Therapies
Cells · 2025
DOI: 10.3390/cells14020065 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, 2025. Verfasst von Wolfgang Eberhardt und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute of General Pharmacology and Toxicology, Goethe University Frankfurt, 60590 Frankfurt, Germany. Hauptthemen laut MEDLINE: Tripartite Motif Proteins, Neoplasms, Ubiquitin-Protein Ligases, Cell Death. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 149 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Research Foundation (DFG).
Abstract (Originalsprache)
Therapy resistance still constitutes a common hurdle in the treatment of many human cancers and is a major reason for treatment failure and patient relapse, concomitantly with a dismal prognosis. In addition to “intrinsic resistance”, e.g., acquired by random mutations, cancer cells typically escape from certain treatments (“acquired resistance”) by a large variety of means, including suppression of apoptosis and other cell death pathways via upregulation of anti-apoptotic factors or through inhibition of tumor-suppressive proteins. Therefore, ideally, the tumor-cell-restricted induction of apoptosis is still considered a promising avenue for the development of novel, tumor (re)sensitizing therapies. A growing body of evidence has highlighted the multifaceted role of tripartite motif 25 (TRIM25) in controlling different aspects of tumorigenesis, including chemotherapeutic drug resistance. Accordingly, overexpression of TRIM25 is observed in many tumors and frequently correlates with a poor patient survival. In addition to its originally described function in antiviral innate immune response, TRIM25 can play critical yet context-dependent roles in apoptotic- and non-apoptotic-regulated cell death pathways, including pyroposis, necroptosis, ferroptosis, and autophagy. The review summarizes current knowledge of molecular mechanisms by which TRIM25 can interfere with different cell death modalities and thereby affect the success of currently used chemotherapeutics. A better understanding of the complex repertoire of cell death modulatory effects by TRIM25 is an essential prerequisite for validating TRIM25 as a potential target for future anticancer therapy to surmount the high failure rate of currently used chemotherapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of General Pharmacology and Toxicology, Goethe University Frankfurt, 60590 Frankfurt, Germany.
Förderung
- German Research Foundation (DFG)
Zitieren
APA
Eberhardt, W., Nasrullah, U., & Pfeilschifter, J. (2025). TRIM25: A Global Player of Cell Death Pathways and Promising Target of Tumor-Sensitizing Therapies. Cells. https://doi.org/10.3390/cells14020065
Vancouver
Eberhardt W, Nasrullah U, Pfeilschifter J. TRIM25: A Global Player of Cell Death Pathways and Promising Target of Tumor-Sensitizing Therapies. Cells. 2025. doi:10.3390/cells14020065
BibTeX
@article{Eberhardt2025,
author = {Eberhardt, Wolfgang and Nasrullah, Usman and Pfeilschifter, Josef},
title = {TRIM25: A Global Player of Cell Death Pathways and Promising Target of Tumor-Sensitizing Therapies},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14020065}
}
EUVIMED